Ulrich Jäger

30PUBLICATIONS
199CO-AUTHORS
Regenerative medicine (incl. stem cells)Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 16, 2026
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

|May 27, 2026
DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.

|Sep 24, 2025
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

Elise R A Pennings, Anne M Spanjaart, Frederick W Thielen

|Jun 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Rakesh Awasthi, Stephan A Grupp, Edward R Waldron

|Feb 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.

Arnon P Kater, Rosemary Harrup, Thomas J Kipps

|Dec 17, 2024
Somatic Recombination Between an Ancient and a Recent NOTCH2 Gene Variant Is Associated with the NOTCH2 Gain-of-Function Phenotype in Chronic Lymphocytic Leukemia.

Rainer Hubmann, Martin Hilgarth, Tamara Löwenstern

Pageof 5

Frequent Collaborators

4 joint publications

Peter Valent

4 joint publications

Marion Subklewe

4 joint publications

Edmund K Waller

3 joint publications

Philipp B Staber